v3.26.1
Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)
3 Months Ended 12 Months Ended
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2025
USD ($)
Working Capital $ 17,400,000    
Retained Earnings (Accumulated Deficit) (187,333,939)   $ (184,137,952)
Cash 22,200,000    
Net Income (Loss) Attributable to Parent (3,195,987) $ (6,432,840)  
Cash, Uninsured Amount $ 825,513   878,844
Financing for Liability Insurance Policy Premiums [Member]      
Debt Instrument, Face Amount     406,875
Proceeds from Short-Term Debt     $ 325,500
Debt Instrument, Interest Rate, Stated Percentage     7.15%
Debt Instrument, Term     10 months
Research and Development Costs [Member] | Supplier Concentration Risk [Member]      
Number of Vendors 1 3  
Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]      
Concentration Risk, Percentage 13.00% 53.00%  
Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member]      
Concentration Risk, Percentage   18.00%  
Research and Development Costs [Member] | Supplier Concentration Risk [Member] | Vendor Three [Member]      
Concentration Risk, Percentage   12.00%